Cost minimisation analysis for darbepoetin alpha vs epoetin alpha in chronic kidney disease patients on haemodialysis
Análisis de minimización de costes de darbepoetina alfa frente a epoetina alfa en pacientes con insuficiencia renal crónica sometidos a hemodiálisis
C. Cuesta Grueso
, J.L. Poveda Andrés, J. Garcia Pellicer, E. Romá Sánchez
Autor para correspondencia
Servicio de Farmacia, Hospital Universitario La Fe, Valencia, Spain
Leído
2334
Vecesse ha leído el artículo
1163
Total PDF
1171
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 30 | 12 | 42 |
| 2025 5 | 82 | 21 | 103 |
| 2025 4 | 66 | 13 | 79 |
| 2025 3 | 49 | 14 | 63 |
| 2025 2 | 56 | 25 | 81 |
| 2025 1 | 40 | 21 | 61 |
| 2024 12 | 29 | 32 | 61 |
| 2024 11 | 45 | 25 | 70 |
| 2024 10 | 10 | 6 | 16 |
| 2024 9 | 38 | 16 | 54 |
| 2024 8 | 45 | 23 | 68 |
| 2024 7 | 30 | 22 | 52 |
| 2024 6 | 24 | 19 | 43 |
| 2024 5 | 26 | 13 | 39 |
| 2024 4 | 25 | 17 | 42 |
| 2024 3 | 23 | 19 | 42 |
| 2024 2 | 30 | 21 | 51 |
| 2024 1 | 23 | 23 | 46 |
| 2023 12 | 27 | 16 | 43 |
| 2023 11 | 18 | 22 | 40 |
| 2023 10 | 20 | 16 | 36 |
| 2023 9 | 21 | 27 | 48 |
| 2023 8 | 17 | 5 | 22 |
| 2023 7 | 15 | 7 | 22 |
| 2023 6 | 17 | 19 | 36 |
| 2023 5 | 13 | 17 | 30 |
| 2023 4 | 13 | 7 | 20 |
| 2023 3 | 9 | 4 | 13 |
| 2023 2 | 7 | 11 | 18 |
| 2022 1 | 8 | 7 | 15 |
| 2022 12 | 10 | 12 | 22 |
| 2022 11 | 5 | 10 | 15 |
| 2022 10 | 8 | 11 | 19 |
| 2022 9 | 5 | 4 | 9 |
| 2022 8 | 14 | 10 | 24 |
| 2022 7 | 8 | 9 | 17 |
| 2022 6 | 12 | 10 | 22 |
| 2022 5 | 9 | 11 | 20 |
| 2022 4 | 7 | 23 | 30 |
| 2022 3 | 6 | 10 | 16 |
| 2022 2 | 6 | 13 | 19 |
| 2021 1 | 3 | 12 | 15 |
| 2021 12 | 5 | 18 | 23 |
| 2021 11 | 4 | 7 | 11 |
| 2021 10 | 7 | 18 | 25 |
| 2021 9 | 6 | 8 | 14 |
| 2021 8 | 3 | 12 | 15 |
| 2021 7 | 1 | 9 | 10 |
| 2021 6 | 4 | 4 | 8 |
| 2021 5 | 3 | 12 | 15 |
| 2021 4 | 7 | 5 | 12 |
| 2021 3 | 4 | 36 | 40 |
| 2021 2 | 3 | 29 | 32 |
| 2020 1 | 5 | 15 | 20 |
| 2020 12 | 6 | 11 | 17 |
| 2020 11 | 1 | 11 | 12 |
| 2020 10 | 2 | 7 | 9 |
| 2020 9 | 6 | 9 | 15 |
| 2020 8 | 7 | 15 | 22 |
| 2020 7 | 6 | 12 | 18 |
| 2020 6 | 3 | 2 | 5 |
| 2020 5 | 3 | 11 | 14 |
| 2020 4 | 1 | 10 | 11 |
| 2020 3 | 3 | 12 | 15 |
| 2020 2 | 0 | 16 | 16 |
| 2020 1 | 0 | 10 | 10 |
| 2019 12 | 7 | 8 | 15 |
| 2019 11 | 0 | 4 | 4 |
| 2019 10 | 1 | 1 | 2 |
| 2019 9 | 1 | 3 | 4 |
| 2019 8 | 1 | 9 | 10 |
| 2019 7 | 4 | 14 | 18 |
| 2019 6 | 8 | 21 | 29 |
| 2019 5 | 27 | 28 | 55 |
| 2019 4 | 1 | 15 | 16 |
| 2019 3 | 2 | 14 | 16 |
| 2019 2 | 1 | 5 | 6 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 1 | 9 | 10 |
| 2018 11 | 2 | 6 | 8 |
| 2018 10 | 3 | 7 | 10 |
| 2018 9 | 2 | 5 | 7 |
| 2018 8 | 1 | 2 | 3 |
| 2018 7 | 0 | 3 | 3 |
| 2018 6 | 1 | 1 | 2 |
| 2018 5 | 0 | 4 | 4 |
| 2018 4 | 0 | 9 | 9 |
| 2018 3 | 2 | 0 | 2 |
| 2018 2 | 0 | 4 | 4 |
| 2018 1 | 0 | 1 | 1 |
| 2017 12 | 2 | 3 | 5 |
| 2017 11 | 2 | 11 | 13 |
| 2017 10 | 3 | 3 | 6 |
| 2017 9 | 1 | 2 | 3 |
| 2017 8 | 3 | 0 | 3 |
| 2017 7 | 6 | 2 | 8 |
| 2017 6 | 5 | 14 | 19 |
| 2017 5 | 1 | 2 | 3 |
| 2017 4 | 2 | 5 | 7 |
| 2017 3 | 4 | 8 | 12 |
| 2017 2 | 2 | 0 | 2 |
| 2016 1 | 1 | 1 | 2 |
| 2016 12 | 6 | 1 | 7 |
| 2016 11 | 6 | 0 | 6 |
| 2016 10 | 6 | 2 | 8 |
| 2016 9 | 8 | 1 | 9 |
| 2016 8 | 7 | 0 | 7 |
| 2016 7 | 2 | 0 | 2 |
Mostrar todo
